CAJ | 학술논문

霍奇金淋巴瘤(Hodgkin’s lymphoma，HL)是一种病因不明的B细胞恶性肿瘤，包括经典型HL和结节性淋巴细胞型HL。为了提高治疗效果和改善病人预后，目前认为针对不同病变分期的HL病人宜采取不同的治疗策略。早期病人主要采用联合物理治疗的方法，通常是短时程联合化疗加低剂量受累淋巴结局部放疗(involved-field radiation therapy，IFRT)。进展期病人建议接受较长时程化疗或增强化疗，但应尽可能减少治疗毒性反应的发生。高剂量化疗加自体干细胞移植(autologous stem cell transplant，ASCT)是目前多数复发/难治性HL病人的标准治疗方法，但ASCT治疗失败后仍然缺乏十分有效的治疗手段。未来研究方向是将更多有效的新型药物整合到一线治疗方案中，进一步提高HL病人的生存预后并减少并发症的发生。
곽기금림파류(Hodgkin’s lymphoma，HL)시일충병인불명적B세포악성종류，포괄경전형HL화결절성림파세포형HL。위료제고치료효과화개선병인예후，목전인위침대불동병변분기적HL병인의채취불동적치료책략。조기병인주요채용연합물리치료적방법，통상시단시정연합화료가저제량수루림파결국부방료(involved-field radiation therapy，IFRT)。진전기병인건의접수교장시정화료혹증강화료，단응진가능감소치료독성반응적발생。고제양화료가자체간세포이식(autologous stem cell transplant，ASCT)시목전다수복발/난치성HL병인적표준치료방법，단ASCT치료실패후잉연결핍십분유효적치료수단。미래연구방향시장경다유효적신형약물정합도일선치료방안중，진일보제고HL병인적생존예후병감소병발증적발생。
Hodgkin’s lymphoma (HL) is a kind of B-cell lymphoid malignancies and the cause of HL remains unknown. HL is composed of two distinct disease entities, including classical HL and nodular lymphocyte-predominant HL. In order to improve the treatment effect and patients prognosis, patients with HL in different stages of disease should take different treatment strategies. Patients with early stage disease are treated with combined modality strategies using abbreviated courses of combination chemotherapy followed by involved-field radiation therapy (IFRT), while those with advanced stage disease receive a longer course of chemotherapy or escalated therapy and should minimize treatment toxicity reaction. High-dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients with relapsed/refractory HL. However, there is still lack of effective drugs for patients who fail with ASCT. hTe future research direction is to integrate more effective new drugs into the ifrst-line treatment scheme for improving the survival of patients and reducing complications.